|Bid||0.0000 x 900|
|Ask||0.0000 x 2900|
|Day's Range||1.9500 - 2.0500|
|52 Week Range||1.6800 - 5.3900|
|Beta (5Y Monthly)||1.11|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 28, 2022 - Mar 04, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||11.00|
Subscribe to Yahoo Finance Plus to view Fair Value for ACERLearn more
Data to be presented suggests ACER-001 could represent a potential alternative to sodium and glycerol phenylbutyrate for treatment of UCDsNEWTON, Mass. and GENEVA, Jan. 27, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER) (“Acer”) and its collaboration partner, RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF) (“Relief”), today announced the acceptance of four ACER-001 abstracts for poster presentations at the upcoming Society for Inherited Metabolic Disorders (SIMD) Annual M
Here is how Opexa Therapeutics, Inc. (ACER) and Aptinyx Inc. (APTX) have performed compared to their sector so far this year.
Just because a business does not make any money, does not mean that the stock will go down. For example, although...